In a country where obesity quietly compounds into crisis, a single regulatory approval has begun to redraw the boundaries of access. Dr. Reddy's Laboratories has received clearance from Indian authorities to manufacture semaglutide — the active compound behind Ozempic and Wegovy — after a patent challenge weakened Novo Nordisk's grip on the Indian market. What was once a treatment reserved for those who could afford a multinational's pricing may now move, slowly but meaningfully, toward the many.
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge Opens Market
Increased access to affordable obesity treatment could improve health outcomes for millions of Indians facing obesity-related health crises.
Health & Medicine